Augustyniak, Monica http://orcid.org/0000-0003-2825-5497
Lou, Emil http://orcid.org/0000-0002-1607-1386
Jacobs, Ginny http://orcid.org/0000-0003-4358-5371
Fleming, Matthew
Marshall, John
Coutinho, Anelisa
Yoshino, Takayuki
Funding for this research was provided by:
Daiichi-Sankyo
Article History
Accepted: 11 November 2023
First Online: 23 December 2023
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and national ethical standards (i.e., US Code of Federal Regulations 21 CFR Parts 50 and 56 and 45 CFR Part 46; the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, TCPS). The research protocol and related documents were reviewed and approved by an Independent Review Board (IRB Veritas, Tracking Number: 2021-2550-8115-1, Study Number: GB-20-010).
: This study involved human participants.
: Only anonymized data from learners who agreed to opt-in via informed consent were included in this study.
: MA is an employee of AXDEV Group, Inc.; EL reports research grants from the American Cancer Society (RSG-22-022-01-CDP) and the Minnesota Ovarian Cancer Alliance; honorarium and travel expenses for a research talk at GlaxoSmithKline; honoraria and travel expenses for lab-based research talks and equipment for laboratory-based research, Novocure, Ltd.; compensation for scientific review of proposed printed content, Elsevier Publishing and Johns Hopkins Press; consultant, Nomocan Pharmaceuticals (no financial compensation); Scientific Advisory Board Member, Minnetronix, LLC, 2018–present (no financial compensation); consultant and speaker honorarium, Boston Scientific US, 2019; Institutional Principal Investigator for clinical trials sponsored by Celgene, Novocure, Intima Biosciences, and the National Cancer Institute, and University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (no financial compensation). GJ is an employee of AXDEV Global Inc.; MF is an employee of Antidote Education Company. JM reports receipt of honorarium from Pfizer, AZ, Merck, Taiho, Bayer, Seagen, Caris, and Indivumed. AC reports involvement in adboards and or speaker for Amgen, Astra Zeneca, Astellas, Bayer, BMS, Merck Group, MSD, Ipsen, Lilly, Novartis, Roche, Pfizer, and Servier. TY reports research grants from Amgen, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, FALCO Biosystems, Genomedia Inc., Molecular Health GmbH, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Sanofi K.K., Sysmex Corp., and Taiho Pharmaceutical; and honorarium from Bayer Yakuhin, Chugai Pharmaceutical, Merck Biopharma, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, and Sumitomo Corp. EL, JM, AC, and TY received an honorarium from Antidote Education Company as part of this educational activity.